These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

490 related articles for article (PubMed ID: 18294246)

  • 1. Efficacy of amoxycillin-clavulanate in an experimental model of murine pneumonia caused by AmpC-non-hyperproducing clinical isolates of Escherichia coli resistant to cefoxitin.
    Docobo-Pérez F; Fernández-Cuenca F; Pachón-Ibáñez ME; Pascual A; Pichardo C; Martínez-Martínez L; Pachón J
    Clin Microbiol Infect; 2008 Jun; 14(6):582-7. PubMed ID: 18294246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Susceptibility to amoxycillin-clavulanate among clinical isolates of Escherichia coli resistant to cefoxitin.
    Fernandez-Cuenca F; Martinez-Martinez L; Amblar G; Biedenbach DJ; Jones RN; Pascual A
    Clin Microbiol Infect; 2006 Feb; 12(2):197-8. PubMed ID: 16441464
    [No Abstract]   [Full Text] [Related]  

  • 3. Prevalent phenotypes and antibiotic resistance in Escherichia coli and Klebsiella pneumoniae at an Indian tertiary care hospital: plasmid-mediated cefoxitin resistance.
    Shahid M; Malik A; Akram M; Agrawal LM; Khan AU; Agrawal M
    Int J Infect Dis; 2008 May; 12(3):256-64. PubMed ID: 17981482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates.
    López-Cerero L; Picón E; Morillo C; Hernández JR; Docobo F; Pachón J; Rodríguez-Baño J; Pascual A
    Clin Microbiol Infect; 2010 Feb; 16(2):132-6. PubMed ID: 19614715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of plasmid-mediated AmpC in Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis.
    Tan TY; Ng SY; Teo L; Koh Y; Teok CH
    J Clin Pathol; 2008 May; 61(5):642-4. PubMed ID: 18057079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Susceptibility of Escherichia coli to the amoxycillin-clavulanate combination: which recommendations should be used to provide relevant information to clinicians?
    Patry I; Hocquet D; Talon D; Plesiat P; Bertrand X
    Clin Microbiol Infect; 2005 Mar; 11(3):237-40. PubMed ID: 15715724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cefotaxime and Amoxicillin-Clavulanate Synergism against Extended-Spectrum-β-Lactamase-Producing Escherichia coli in a Murine Model of Urinary Tract Infection.
    Rossi B; Soubirou JF; Chau F; Massias L; Dion S; Lepeule R; Fantin B; Lefort A
    Antimicrob Agents Chemother; 2016 Jan; 60(1):424-30. PubMed ID: 26525800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The AmpC inhibitor, Syn2190, can be used to reveal extended-spectrum beta-lactamases in Escherichia coli.
    Netzel TC; Jindani I; Hanson N; Turner BM; Smith L; Rand KH
    Diagn Microbiol Infect Dis; 2007 Jul; 58(3):345-8. PubMed ID: 17379469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. β-Lactamases in amoxicillin-clavulanate-resistant Escherichia coli strains isolated from a Chinese tertiary hospital.
    Ding J; Ma X; Chen Z; Feng K
    Diagn Microbiol Infect Dis; 2013 Aug; 76(4):532-3. PubMed ID: 23726651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.
    Rodríguez-Baño J; Alcalá JC; Cisneros JM; Grill F; Oliver A; Horcajada JP; Tórtola T; Mirelis B; Navarro G; Cuenca M; Esteve M; Peña C; Llanos AC; Cantón R; Pascual A
    Arch Intern Med; 2008 Sep; 168(17):1897-902. PubMed ID: 18809817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Investigation of plasmid-mediated AmpC beta-lactamase types in Klebsiella spp. and Escherichia coli isolates resistant or intermediate to cefoxitin].
    Demirbakan H; Midilli K; Oğünç D; Ozen N; Ongüt G; Dağlar D; Mutlu D; Ozhak B; Colak D
    Mikrobiyol Bul; 2008 Oct; 42(4):545-51. PubMed ID: 19149075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum beta-lactamases, AmpC beta-lactamases and reduced susceptibility to carbapenems using an in vitro model.
    Zhanel GG; Baudry PJ; Tailor F; Cox L; Hoban DJ; Karlowsky JA
    J Antimicrob Chemother; 2009 Oct; 64(4):824-8. PubMed ID: 19643776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ampC gene expression in promoter mutants of cefoxitin-resistant Escherichia coli clinical isolates.
    Tracz DM; Boyd DA; Hizon R; Bryce E; McGeer A; Ofner-Agostini M; Simor AE; Paton S; Mulvey MR;
    FEMS Microbiol Lett; 2007 May; 270(2):265-71. PubMed ID: 17326753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased expression levels of chromosomal AmpC β-lactamase in clinical Escherichia coli isolates and their effect on susceptibility to extended-spectrum cephalosporins.
    Paltansing S; Kraakman M; van Boxtel R; Kors I; Wessels E; Goessens W; Tommassen J; Bernards A
    Microb Drug Resist; 2015 Feb; 21(1):7-16. PubMed ID: 25188329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. beta-Lactam resistance phenotype determination in Escherichia coli isolates from University Malaya Medical Centre.
    Wong JS; Mohd Azri ZA; Subramaniam G; Ho SE; Palasubramaniam S; Navaratnam P
    Malays J Pathol; 2003 Dec; 25(2):113-9. PubMed ID: 16196367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emergence of imipenem resistance in clinical Escherichia coli during therapy.
    Oteo J; Delgado-Iribarren A; Vega D; Bautista V; Rodríguez MC; Velasco M; Saavedra JM; Pérez-Vázquez M; García-Cobos S; Martínez-Martínez L; Campos J
    Int J Antimicrob Agents; 2008 Dec; 32(6):534-7. PubMed ID: 18775649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Susceptibility of canine and feline Escherichia coli and canine Staphylococcus intermedius isolates to fluoroquinolones.
    Gottlieb S; Wigney DI; Martin PA; Norris JM; Malik R; Govendir M
    Aust Vet J; 2008 Apr; 86(4):147-52. PubMed ID: 18363989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity in vitro of twelve antibiotics against clinical isolates of extended-spectrum beta-lactamase producing Escherichia coli.
    Sorlózano A; Gutiérrez J; Romero JM; de Dios Luna J; Damas M; Piédrola G
    J Basic Microbiol; 2007 Oct; 47(5):413-6. PubMed ID: 17910106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Investigation of the frequency of extended spectrum beta-lactamases and antibiotic resistance in clinical isolates of Escherichia coli and Klebsiella sp].
    Ekşi F; Ozer G; Balci I
    Mikrobiyol Bul; 2007 Jul; 41(3):447-52. PubMed ID: 17933257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Escherichia coli from community-acquired urinary tract infections resistant to fluoroquinolones and extended-spectrum beta-lactams.
    Kariuki S; Revathi G; Corkill J; Kiiru J; Mwituria J; Mirza N; Hart CA
    J Infect Dev Ctries; 2007 Dec; 1(3):257-62. PubMed ID: 19734602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.